MD

Business Context and Reporting Period

Pediatrix Medical Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2001. The Company is a Florida-based provider of neonatal, newborn, and pediatric services. The reporting period is significantly impacted by the completion of a merger with Magella Healthcare Corporation on May 15, 2001, and the acquisition of five additional physician group practices during the nine months ended September 30, 2001.

Key Financial Metrics

Liquidity: The Company reported a net increase in cash of $0.5 million for the nine-month period. Operating cash flow was $58.6 million, while investing activities used $27.4 million (primarily for acquisitions) and financing activities used $30.8 million (primarily debt repayments).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 59.9% for the quarter and 39.6% for the nine-month period compared to 2000. Approximately 88% of the quarterly increase and 83% of the nine-month increase were attributable to new units from acquisitions (Magella and others).
• Profitability: Net income increased 169% for the quarter and 193% for the nine-month period. Operating income rose 135% for the quarter and 141% for the nine-month period.
• Expense Increases: Salaries and benefits increased 46.5% (quarter) and 27.7% (nine months), driven primarily by the addition of staff from the Magella merger. Depreciation and amortization increased 82.4% (quarter) due to goodwill amortization.
• Balance Sheet: Total assets grew from $324.7 million to $547.0 million, largely due to goodwill and other assets recorded from the Magella merger ($106.7 million in goodwill). Shareholders' equity increased from $241.9 million to $459.0 million due to stock issuance for the merger and retained earnings.

Guidance, Outlook, Risks, and Contingencies

Management Commentary: Management attributes growth to pricing increases, volume increases, and higher acuity levels. The Company expects funds from operations and its $100 million line of credit (refinanced in Q3 2001) to be sufficient for working capital and capital expenditures for the next 12 months.

Legal Proceedings and Contingencies:

• Securities Class Action: A federal securities class action regarding billing practices and misleading statements (filed Feb 1999) remains pending. A pre-trial conference is set for November 19, 2001. The Company believes claims are without merit but notes potential damages could exceed insurance coverage.
• Government Investigations: Investigations into Medicaid billing practices in Arizona and Florida were settled in 2000 (total payments of $260,000 plus costs). An investigation in Colorado remains ongoing, and inquiries have been initiated in other states. The Company cannot predict the outcome of the Colorado investigation.
• Medical Malpractice: Pending actions are generally covered by insurance and are not expected to have a material impact.

Accounting Changes: The Company adopted FAS 141 and FAS 142 effective July 1, 2001. Goodwill from acquisitions after June 30, 2001, is no longer amortized. The adoption did not have a material impact on results for the quarter.

Investor Verification Checklist

• Merger Integration: Verify the sustainability of revenue growth from the Magella merger and the integration of acquired physician groups.
• Legal Exposure: Monitor the status of the federal securities class action and the ongoing Colorado Medicaid investigation for potential material liabilities.
• Debt Covenants: Confirm continued compliance with financial covenants under the new $100 million line of credit maturing in 2004.
• Goodwill Valuation: Assess the impact of FAS 142 on future financial statements, specifically regarding the annual impairment testing of the significant goodwill balance ($454.7 million).
• Reimbursement Rates: Evaluate the stability of third-party payer reimbursement rates, which management cites as a driver for same-unit revenue growth.